Evidence map›Paper›PMID 36532756›Full record

ArticleFrontiers in pharmacology2022

A novel biflavone from

Jianqiong Yang, Bang Xiao, Yamei Li, Xiaoxuan Liu, Minhong Zhang, Yaoling Luo, Biao Wang, Hai Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jianqiong YangThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Bang XiaoThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Yamei LiThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Xiaoxuan LiuThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Minhong ZhangThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Yaoling LuoThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Biao WangThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Hai LiuThe Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Gannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system, which is highly invasive, metastatic, and insensitive to radiotherapy and chemotherapy. Chinese herbal medicine has always been an important source of anti-tumor drug development.

Indexed as

apoptosischemical constituentshuman renal cancer 786-O cellsreineckia-biflavone AReineckia carnea

Identifiers

PMID36532756
PMCPMC9756134
OpenAlexW4311048309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.